Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M92,993Revenue $M18,676Net Margin (%)27.2Z-Score2.0
Enterprise Value $M105,215EPS $6.6Operating Margin %31.4F-Score5
P/E(ttm))19.8Cash Flow Per Share $6.7Pre-tax Margin (%)28.2Higher ROA y-yN
Price/Book3.910-y EBITDA Growth Rate %11.0Quick Ratio3.1Cash flow > EarningsY
Price/Sales5.05-y EBITDA Growth Rate %8.7Current Ratio3.5Lower Leverage y-yY
Price/Cash Flow13.3y-y EBITDA Growth Rate %11.3ROA % (ttm)7.7Higher Current Ratio y-yN
Dividend Yield %1.8Insider Buy (3m)1ROE % (ttm)23.0Less Shares Outstanding y-yN
Payout Ratio %33.0Shares Outstanding M757ROI % (ttm)8.2Gross Margin Increase y-yN

Gurus Latest Trades with AMGN

Number of guru portfolios checked: 56.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
AMGNMario Gabelli 2014-03-31 Add0.01%$113.48 - $127.47
($121.04)
$ 122.842%Add 37.87%32,565
AMGNDodge & Cox 2014-03-31 Reduce$113.48 - $127.47
($121.04)
$ 122.842%Reduce -22.59%105,757
AMGNPRIMECAP Management 2014-03-31 Reduce-0.46%$113.48 - $127.47
($121.04)
$ 122.842%Reduce -9.42%32,161,744
AMGNJohn Hussman 2014-03-31 Reduce-0.2%$113.48 - $127.47
($120.95)
$ 122.842%Reduce -14.29%150,000
AMGNVanguard Health Care Fund 2014-03-31 Reduce-0.2%$113.48 - $127.47
($120.95)
$ 122.842%Reduce -6.4%8,213,855
AMGNJoel Greenblatt 2014-03-31 Sold Out -0.06%$113.48 - $127.47
($121.04)
$ 122.842%Sold Out0
AMGNRay Dalio 2014-03-31 Sold Out -0.01%$113.48 - $127.47
($121.04)
$ 122.842%Sold Out0
AMGNJoel Greenblatt 2013-12-31 Buy 0.06%$106.28 - $118.688
($113.73)
$ 122.848%New holding, 23170 sh.23,170
AMGNRay Dalio 2013-12-31 Buy 0.01%$106.28 - $118.688
($113.73)
$ 122.848%New holding, 7513 sh.7,513
AMGNVanguard Health Care Fund 2013-12-31 Reduce-0.76%$106.28 - $118.688
($113.73)
$ 122.848%Reduce -18.43%8,775,155
AMGNJohn Hussman 2013-12-31 Reduce-0.45%$106.28 - $118.688
($113.73)
$ 122.848%Reduce -30%175,000
AMGNJohn Hussman 2013-09-30 Add0.3%$95.81 - $117.521
($108.55)
$ 122.8413%Add 25%250,000
AMGNMario Gabelli 2013-09-30 Add$95.81 - $117.521
($108.55)
$ 122.8413%Add 26.95%22,420
AMGNPRIMECAP Management 2013-09-30 Reduce-0.22%$95.81 - $117.521
($108.55)
$ 122.8413%Reduce -4.11%35,812,225
AMGNRay Dalio 2013-09-30 Sold Out -0.07%$95.81 - $117.521
($108.55)
$ 122.8413%Sold Out0
AMGNDodge & Cox 2013-09-30 Reduce-0.01%$95.81 - $117.521
($108.55)
$ 122.8413%Reduce -38.73%160,052
AMGNMario Gabelli 2013-06-30 Reduce$94.6 - $113.42
($103.77)
$ 122.8418%Reduce -22.17%17,660
AMGNJohn Hussman 2013-06-30 Reduce-1.14%$94.6 - $113.42
($103.77)
$ 122.8418%Reduce -60%200,000
AMGNPRIMECAP Management 2013-06-30 Reduce-0.38%$94.6 - $113.42
($103.77)
$ 122.8418%Reduce -6.36%37,348,991
AMGNVanguard Health Care Fund 2013-06-30 Reduce-0.29%$94.6 - $113.42
($103.77)
$ 122.8418%Reduce -6.41%10,758,455
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

AMGN is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
AMGN Mario Gabelli 2014-03-3132,56500.02+37.87%
AMGN Vanguard Health Care Fund 2014-03-318,213,8551.092.8-6.4%
AMGN PRIMECAP Management 2014-03-3132,161,7444.254.5-9.42%
AMGN John Hussman 2014-03-31150,0000.021.4-14.29%
AMGN Dodge & Cox 2014-03-31105,7570.010.01-22.59%
AMGN Joel Greenblatt 2014-03-31000Sold Out
AMGN Ray Dalio 2014-03-31000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


AMGN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Dittrich Thomas J.W.VP, Finance & CAO 2014-05-21Sell4,130$112.838.36view
Bradway Robert AChairman, CEO and President 2014-05-12Buy894$111.779.39view
Michael A KellyActing CFO 2014-04-28Sell2,065$110.4510.69view
de Carbonnel FrancoisDirector 2014-03-06Sell1,000$126.69-3.5view
HENDERSON REBECCA MDirector 2014-02-13Sell20,000$123.53-1.03view
AMGEN INC10% Owner 2013-12-17Buy272,142$71646.57view
Balachandran MadhavanEVP, Operations 2013-09-04Sell18,000$112.768.42view
BALTIMORE DAVIDDirector 2013-08-28Sell4,582$109.6611.49view
Dittrich Thomas J.W.VP, Finance & CAO 2013-05-22Sell6,130$104.7816.68view
Balachandran MadhavanEVP, Operations 2013-05-21Sell6,000$103.2818.38view

Press Releases about AMGN :

    Quarterly/Annual Reports about AMGN:

    News about AMGN:

    Articles On GuruFocus.com
    Gulf Resources (GURE) Impressive Performance, Amgen (AMGN) and AstraZeneca (AZN) Positive Data From May 11 2014 
    Amgen Inc: As Good as It Gets? Feb 20 2014 
    You Can No Longer Ignore Biotech Feb 07 2014 
    Mario Gabelli Comments on Amgen Inc. Jan 06 2014 
    The Gabelli Asset Fund Shareholder Commentary - Third Quarter Jan 06 2014 
    38 Stocks with Higher Dividends Dec 23 2013 
    Vanguard Health Care Fund’s Top Third Quarter Holdings Oct 31 2013 
    Insiders Are Buying Idera Pharmaceuticals Sep 19 2013 
    PRIMECAP Trims Top Biotechs and More Aug 30 2013 
    Amgen’s Dividend Policy Has Ignited Its Stock Jan 11 2013 


    More From Other Websites
    Bayer and Onyx Pharmaceuticals Report Phase 3 Trial Results of NEXAVAR® (sorafenib) in Patients... Jul 25 2014
    Amgen Announces Webcast of 2014 Second Quarter Financial Results Jul 24 2014
    FDA reviewing what could be first biosimilar drug Jul 24 2014
    Amgen Announces Webcast of 2014 Second Quarter Financial Results Jul 24 2014
    [video] Power Countdown: Biotech, social & Internet Jul 23 2014
    Do You Have The Best or Worst 401(k) Plan? Jul 23 2014
    Amgen Can Propel Over $120 With Earnings Right Around The Corner Jul 22 2014
    [video] Which Company Offers the Best 401(k) Plan? Jul 22 2014
    Amgen's AMG 416 Succeeds in Phase III, Shares Up Jul 21 2014
    Amgen: Grappling With The Reality Of Patent Expiries Jul 18 2014
    Amgen parathyroid drug found effective in kidney patient trial Jul 17 2014
    Amgen Announces Positive Phase 3 Results for AMG 416 for the Treatment of Secondary... Jul 17 2014
    [$$] Amgen Hormone Drug Proves Positive in Study Jul 17 2014
    Amgen thyroid drug succeeds in late stage kidney patient trial Jul 17 2014
    Amgen Announces Positive Phase 3 Results for AMG 416 for the Treatment of Secondary... Jul 17 2014
    Amgen (AMGN) Roof Leaking Today Jul 15 2014
    Facebook, Twitter slip following cautious valuation comments from Fed Jul 15 2014
    Celgene Drug Otezla Fails Trial, But Street Sanguine Jul 09 2014
    Alexion Pharma Looks To Life Beyond Its Blockbuster Jul 08 2014
    BIND Therapeutics Ends Oncology Deal with Amgen Jul 03 2014

    Add Notes, Comments or Ask Questions

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK
    Email Hide